Table 3 Summary of subgroup analysis with random effects SMD (95% CI).

From: Serum and supplemental vitamin D levels and insulin resistance in T2DM populations: a meta-analysis and systematic review

Subgroups

FBG

FI

HOMA-IR

Correlation coefficient between VD and HOMA-IR

Dose

 < 50,000 IU/week

 − 3.9(− 0.63, − 0.16)

 − 0.70(− 0.96, − 0.440

 − 0.66(− 0.89, − 0.43)

NA

 ≥ 50,000 IU/week

 − 0.7(− 0.23, 0.09)

 − 0.12(− 0.27, 0.03)

 − 0.32(− 0.49, − 0.14)

NA

Duration

 < 4 months

 − 0.34(− 0.52, − 0.15)

 − 0.67(− 0.86, − 0.47)

 − 0.81(− 0.99, − 0.64)

NA

 ≥ 4 months

0.01(− 0.18, 0.19)

0.07(− 0.1, 0.25)

0.20(− 0.03, 0.43)

NA

Vitamin D levels

Replete

NA

NA

 − 0.08(− 0.55, 0.39)

NA

Insufficiency

0.11(− 0.12, 0.34)

0.09(− 0.14, 0.32)

0.03(− 0.67, 0.72)

 − 0.36(− 0.49, − 0.04)

Deficiency

 − 0.31(− 0.47, − 0.15)

 − 0.43(− 0.58, − 0.27)

 − 0.5(− 0.65, − 0.35)

 − 0.05(− 0.07, − 0.03)

  1. NA not analyzed, FBG Fasting Blood Glucose, HOMA-IR Homeostasis Model Assessment-Insulin Resistance, FI Fasting Insulin, VD Vitamin D.
  2. *Statistically significant variables at P value < 0.05.
Back to article page